Ratio Therapeutics Secures $70 Million in Series C Funding
Ratio Therapeutics has successfully closed a $70 million Series C funding round, according to an announcement made on July 31, 2026. The funding was led by Duquesne Family Office, with significant contributions from Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, and Wasatch Group.
Company Overview
Ratio Therapeutics is focused on the development of targeted radiotherapeutics, an innovative approach in oncology treatment. The company aims to enhance the precision and effectiveness of radiopharmaceuticals, offering new hope in the fight against cancer.
Strategic Use of Funds
The newly acquired funds are earmarked for several key initiatives. A significant portion will be directed towards advancing the ATLAS study, which evaluates the company's lead radiotherapeutic asset, Ac-225 RTX-2358, in the treatment of advanced sarcomas. This study is a cornerstone of Ratio's development pipeline.
Additionally, the company plans to move its next-generation radioligand therapy (RLT) candidate into clinical trials. This step is crucial for expanding its impact in oncology.
Pipeline and Manufacturing Expansion
The funding will also support the expansion of Ratio's discovery pipeline, targeting new oncology indications. To facilitate this growth, the company intends to enhance its manufacturing capabilities. This will be anchored by its vertically integrated site in Utah, which plays a pivotal role in ensuring the supply chain for its radiopharmaceuticals.
Leadership Comments
Jack Hoppin, CEO of Ratio Therapeutics, expressed optimism about the funding's impact, stating: "This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead."
Conclusion
With this substantial investment, Ratio Therapeutics is well-positioned to advance its clinical development efforts and strengthen its radiopharmaceutical platform. The backing from high-profile investors underscores the potential impact of Ratio's innovative approach in the field of oncology.